Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
StockNews.com began coverage on shares of Grifols (NASDAQ:GRFS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock. A number of other equities analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Grifols from a sell rating […]
Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) gapped up before the market opened on Friday . The stock had previously closed at $10.38, but opened at $10.73. Grifols shares last traded at $10.73, with a volume of 200 shares. Several research firms have commented on GRFS. Berenberg Bank decreased their price target on shares […]
Zacks Investment Research upgraded shares of Grifols (NASDAQ:GRFS – Get Rating) from a sell rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and […]
Grifols, S.A. (NASDAQ:GRFS – Get Rating) fell 5.7% on Thursday . The company traded as low as $11.74 and last traded at $12.00. 19,518 shares were traded during trading, a decline of 98% from the average session volume of 891,836 shares. The stock had previously closed at $12.73. A number of research firms have recently […]